New patch therapy: A breakthrough for peanut allergy sufferers

NewsGuard 100/100 Score

The Food Allergy Center at Rady Children's Hospital-San Diego is one of eight hospitals in the United States participating in an international peanut allergy desensitization study. The investigational therapy involves participants wearing a skin patch that contains tiny amounts of peanut. The purpose of the study is to see if people wearing the patch for a certain period of time will develop lower sensitivity to peanut.

"There are almost 3,000 children seen at Rady Children's who report a peanut allergy. Until now we have had no treatment to offer, instead management has involved avoidance and treatment of accidental ingestions. The new patch therapy could prove to be a breakthrough for the peanut allergy sufferers," said Stephanie Leonard, M.D., director, of the Food Allergy Center at Rady Children's. "This type of groundbreaking clinical research is important for our community."

About one percent of people in the United States or about 3 million of the population suffer from peanut allergies and that number is increasing. Only 20 percent of children may outgrow a peanut allergy.

Rady Children's is looking for children who suffer from a peanut allergy to participate in the research. Some of the requirements include:

• Participants must be healthy and at least 6 years old
• Have eaten peanut and had a reaction and are currently following a strictly peanut-free diet
• Willing to wear a daily skin patch
• Participate in 12 clinic visits during the course of 13 months

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stapokibart shows promise in reducing nasal congestion in seasonal allergy patients, study finds